Get alerts:President and CEO Joe Payne said the company’s Phase II study of ARCT-032, an inhaled mRNA treatment candidate for cystic fibrosis, remains on schedule. Arcturus expects to decide whether to advance ARCT-032 into Phase III during the fourth quarter of 2026. Arcturus is preparing for regulatory discussions, including an end-of-Phase-II meeting addressing potential adult and pediatric development paths. Arcturus plans to seek scientific advice from the European Medicines Agency regarding a potential licensure path later in 2026. About Arcturus Therapeutics (NASDAQ:ARCT)Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases.